Trial · NCT07353723
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
NCT07353723, Phase 2, Recruiting, Tang-Du Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer. Trials, record NCT07353723. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07353723
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
- NCT number
- NCT07353723
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Tang-Du Hospital
- Conditions
- Head & Neck Cancer
- Interventions
- Nimotuzumab, Toripalimab, Nab-paclitaxel, carboplatin
- First posted
- 2026-01-20
- Last updated
- 2026-01-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response rate (pCR) | Within 1-2 week after radical surgery (same time point as MPR assessment) | no residual tumor cells in the primary lesion and lymph nodes after surgery (pathological assessment). |
| Secondary | Surgical resection margin (first margin and second margin) | Within 1-2 week after radical surgery (performed 2-3 weeks after the completion of 2 cycles of neoadjuvant treatment) | First margin: tumor margin before neoadjuvant therapy; Second margin: tumor margin after neoadjuvant therapy (defined as Clear margin per the 2025 NCCN Guidelines: the distance from invasive tumor to the resection margin ≥ 5 mm). |
| Secondary | Major pathological response rate (MPR) | Within 1-2 week after radical surgery (performed 2-3 weeks after the completion of 2 cycles of neoadjuvant treatment) | residual tumor in the primary lesion \< 10% (pathological assessment). |
| Secondary | Radiological response rate | After the completion of 2 cycles of neoadjuvant treatment (each cycle is 21 days) | evaluated by contrast-enhanced CT/MRI before and after treatment (per RECIST 1.1 criteria: complete response \[CR\]/partial response \[PR\]/stable disease \[SD\]/progressive disease \[PD\]). |
| Secondary | Functional preservation rate | functional assessment: before surgery,and 1 month, 6 months, and 1 year after surgery or Concurrent chemoradiotherapy | Functional preservation rate was defined as the proportion of patients with normal phonation and swallowing function: before surgery, and 1 month, 6 months, and 1 year after surgery or radiotherapy (evaluated via video laryngoscopy + scale assessment + voice analysis) |
| Secondary | Disease-free survival (DFS) | 72 months after treatment initiation | the time from the initiation of radical treatment to the first occurrence of disease recurrence, metastasis, second primary cancer, or death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42523785 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07353723
GET https://conductscience.org/api/trials/v1/NCT07353723/registered